BioCentury
ARTICLE | Clinical News

bluebird updates LentiGlobin sickle cell data

June 16, 2015 2:10 AM UTC

bluebird bio Inc. (NASDAQ:BLUE) said a sickle cell disease (SCD) patient treated with LentiGlobin BB305 gene therapy has remained transfusion independent for three months since receiving his last transfusion 88 days post-transplant. Data from the ongoing Phase I/II French HGB-205 study were presented at the European Hematology Association (EHA) meeting.

At 6 months post-transplant, 45% of the patient's total hemoglobin consisted of "anti-sickling" hemoglobin. According to bluebird, SCD patients with red blood cells containing at least 30% anti-sickling hemoglobin "could significantly improve and potentially eliminate the serious and life-threatening complications" associated with SCD. The patient has not had any post-transplant hospitalizations for complications related to SCD. ...